SCM
OBIO icon

Sterling Capital Management’s Orchestra BioMed OBIO Stock Holding History

Sterling Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-247
Closed -$1.06K – 3352
2025
Q1 		$1.06K Sell
247
-215
-47% -$1.07K ﹤0.01% 2793
2024
Q4 		$1.85K Buy
462
+409
+772% +$2.2K ﹤0.01% 2803
2024
Q3 		$272 Buy
+53
New +$346 ﹤0.01% 3055

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's OBIO Position: Q2 2025 in Review

Sterling Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 247 shares — an estimated $1.06K sold.

Sterling Capital Management first reported a position in OBIO in Q3 2024 and held it in 3 quarters. The position peaked at $1.85K in Q4 2024. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Sterling Capital Management reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 247 Orchestra BioMed shares in Q2 2025, an estimated $1.06K.
  • Sterling Capital Management first reported a position in Orchestra BioMed in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Orchestra BioMed position peaked at $1.85K in Q4 2024.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.